FindTrial
Sign In

Paclitaxel for injection (albumin-bound)

DRUG5 trials

Sponsors

Huazhong University of Science and Technology, Guangzhou Institute of Respiratory Disease, CSPC Ouyi Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., The First Affiliated Hospital of Xiamen University

Conditions

Advanced Breast CancerAdvanced MalignanciesEsophageal Squamous Cell CarcinomaGastric/Gastroesophageal Junction AdenocarcinomaImmunotherapyMetastatic Breast CancerOvarian CancerRecurrent Breast Cancer

Phase 1

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
RecruitingNCT06202261
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignancies, Metastatic Breast Cancer, Recurrent Breast Cancer
Start: 2023-04-13End: 2027-10-31Target: 154Updated: 2024-03-12

Phase 2

Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer
NCT03818282
Huazhong University of Science and TechnologyOvarian Cancer
Start: 2019-03-01End: 2024-12-31Target: 77Updated: 2019-02-26
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
CompletedNCT04225364
Guangzhou Institute of Respiratory DiseaseEsophageal Squamous Cell Carcinoma, Immunotherapy
Start: 2020-01-17End: 2021-01-31Updated: 2021-02-02
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
RecruitingNCT06415669
The First Affiliated Hospital of Xiamen UniversityGastric/Gastroesophageal Junction Adenocarcinoma
Start: 2024-05-19End: 2027-05-19Target: 30Updated: 2024-05-29

Phase 3

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
NCT05753865
CSPC Ouyi Pharmaceutical Co., Ltd.Advanced Breast Cancer
Start: 2023-05-01End: 2024-09-01Target: 454Updated: 2023-03-03

Related Papers

Abstract PS1-09-24: Efficacy and safety of Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-blind Phase III study
Clinical Cancer Research2026-02-17
Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study.
Journal of Clinical Oncology2025-05-28
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.
Journal of Clinical Oncology2024-06-013 citations
Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
2021-11-1023 citations
Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
Journal of Clinical Oncology2021-05-2011 citations
Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).
2020-06-2718 citations